OraSure Technologies, Inc. (OTI) has made a significant stride in proteomic research with the launch of its HEMAcollect™ PROTEIN blood collection device, developed by its subsidiary DNA Genotek. This innovative product is an evacuated blood collection tube (BCT) designed to overcome key limitations in current proteomic sample management.

The core innovation lies in the device's proprietary stabilizing liquid, which ensures the preservation and stability of plasma proteins in whole blood for an extended period – up to seven days – at ambient temperatures. This eliminates the need for immediate processing or cold chain logistics, which are often costly and logistically challenging, especially in diverse geographical settings.

Powered by ProteoPrecision™ technology, the HEMAcollect™ PROTEIN BCT actively minimizes common issues like hemolysis and platelet activation. These issues can introduce artifacts into samples, potentially skewing research results. By ensuring a more accurate reflection of the body's state at the time of collection, the device facilitates the generation of higher-quality, more reliable proteomic data.

Currently available for research use only, the HEMAcollect™ PROTEIN BCT is broadly compatible with a variety of downstream proteomic technologies, including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. This versatility positions it as a valuable tool for researchers across numerous fields, such as oncology, neurology, cardiology, and metabolic disorders. The anticipated operational and financial efficiencies, coupled with improved data integrity, are expected to significantly advance proteomic discovery and ultimately contribute to a deeper understanding of human health and disease.